Oncothyreon Stock Hits New 52-Week Low (ONTY)
NEW YORK (TheStreet) -- Oncothyreon (Nasdaq:ONTY) hit a new 52-week low Wednesday as it is currently trading at $3.93, below its previous 52-week low of $3.94 with 373,921 shares traded as of 3:16 p.m. ET. Average volume has been 1.2 million shares over the past 30 days. Oncothyreon has a market cap of $229.1 million and is part of the health care sector and drugs industry. Shares are down 47.2% year to date as of the close of trading on Tuesday. Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
Latest Headlines about ONTY
-
ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine
06:00PM 05/15/13
-
4 Biotech Stocks Under $10 Making Big Moves
02:17PM 04/09/13
-
5 Stocks Under $10 Set to Soar
01:36PM 02/28/13
-
3 Pharma Stocks Leaping on Unusual Volume
02:18PM 01/10/13
-
Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon
07:00AM 12/21/12
-
Stocks Slump for First Time This Week as Fiscal-Cliff Talks Skid
04:38PM 12/19/12
-
Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study
10:34AM 12/19/12
Latest from TheStreet Wire
-
Avago Technologies Ltd (AVGO): Today's Featured Electronics Laggard
05:01PM 05/23/13
-
Wynn Resorts Ltd (WYNN): Today's Featured Services Laggard
05:01PM 05/23/13
-
Pentair Ltd (PNR): Today's Featured Industrial Laggard
05:01PM 05/23/13
-
Microsoft Corporation (MSFT): Today's Featured Computer Software & Services Laggard
05:01PM 05/23/13
-
Michael Kors Holdings Ltd (KORS): Today's Featured Retail Laggard
05:01PM 05/23/13
-
Devon Energy Corp (DVN): Today's Featured Basic Materials Laggard
05:01PM 05/23/13
-
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard
05:01PM 05/23/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
